149 related articles for article (PubMed ID: 29392178)
1. Comparative Nucleotide-Dependent Interactome Analysis Reveals Shared and Differential Properties of KRas4a and KRas4b.
Zhang X; Cao J; Miller SP; Jing H; Lin H
ACS Cent Sci; 2018 Jan; 4(1):71-80. PubMed ID: 29392178
[TBL] [Abstract][Full Text] [Related]
2. KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform.
Salmón M; Paniagua G; Lechuga CG; Fernández-García F; Zarzuela E; Álvarez-Díaz R; Musteanu M; Guerra C; Caleiras E; Muñoz J; Ortega S; Drosten M; Barbacid M
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301865
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of KRAS4a and KRAS4b splice variants reveals distinctive structural and functional properties.
Whitley MJ; Tran TH; Rigby M; Yi M; Dharmaiah S; Waybright TJ; Ramakrishnan N; Perkins S; Taylor T; Messing S; Esposito D; Nissley DV; McCormick F; Stephen AG; Turbyville T; Cornilescu G; Simanshu DK
Sci Adv; 2024 Feb; 10(7):eadj4137. PubMed ID: 38354232
[No Abstract] [Full Text] [Related]
4. A Proteomic Approach Identifies Isoform-Specific and Nucleotide-Dependent RAS Interactions.
Miller SP; Maio G; Zhang X; Badillo Soto FS; Zhu J; Ramirez SZ; Lin H
Mol Cell Proteomics; 2022 Aug; 21(8):100268. PubMed ID: 35839996
[TBL] [Abstract][Full Text] [Related]
5. KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab.
Chiari R; Palladino S; Emili R; De Lisa M; Sarti D; Catalano V; Magnani M; Graziano F; Ruzzo A
Sci Rep; 2023 Nov; 13(1):21036. PubMed ID: 38030703
[TBL] [Abstract][Full Text] [Related]
6. The role of KRAS splice variants in cancer biology.
Nuevo-Tapioles C; Philips MR
Front Cell Dev Biol; 2022; 10():1033348. PubMed ID: 36393833
[TBL] [Abstract][Full Text] [Related]
7. Differential functions of the KRAS splice variants.
Kochen Rossi J; Nuevo-Tapioles C; Philips MR
Biochem Soc Trans; 2023 Jun; 51(3):1191-1199. PubMed ID: 37222266
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.
Chen WC; To MD; Westcott PMK; Delrosario R; Kim IJ; Philips M; Tran Q; Bollam SR; Goodarzi H; Bayani N; Mirzoeva O; Balmain A
Nat Commun; 2021 Jul; 12(1):4288. PubMed ID: 34257283
[TBL] [Abstract][Full Text] [Related]
10. Mapping the KRAS proteoform landscape in colorectal cancer identifies truncated KRAS4B that decreases MAPK signaling.
Adams LM; DeHart CJ; Drown BS; Anderson LC; Bocik W; Boja ES; Hiltke TM; Hendrickson CL; Rodriguez H; Caldwell M; Vafabakhsh R; Kelleher NL
J Biol Chem; 2023 Jan; 299(1):102768. PubMed ID: 36470426
[TBL] [Abstract][Full Text] [Related]
11. KRAS4A directly regulates hexokinase 1.
Amendola CR; Mahaffey JP; Parker SJ; Ahearn IM; Chen WC; Zhou M; Court H; Shi J; Mendoza SL; Morten MJ; Rothenberg E; Gottlieb E; Wadghiri YZ; Possemato R; Hubbard SR; Balmain A; Kimmelman AC; Philips MR
Nature; 2019 Dec; 576(7787):482-486. PubMed ID: 31827279
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of recognition of farnesylated and methylated KRAS4b by PDEδ.
Dharmaiah S; Bindu L; Tran TH; Gillette WK; Frank PH; Ghirlando R; Nissley DV; Esposito D; McCormick F; Stephen AG; Simanshu DK
Proc Natl Acad Sci U S A; 2016 Nov; 113(44):E6766-E6775. PubMed ID: 27791178
[TBL] [Abstract][Full Text] [Related]
13. The quaternary assembly of KRas4B with Raf-1 at the membrane.
Jang H; Zhang M; Nussinov R
Comput Struct Biotechnol J; 2020; 18():737-748. PubMed ID: 32257057
[TBL] [Abstract][Full Text] [Related]
14. Roles of palmitoylation and the KIKK membrane-targeting motif in leukemogenesis by oncogenic KRAS4A.
Zhao H; Liu P; Zhang R; Wu M; Li D; Zhao X; Zhang C; Jiao B; Chen B; Chen Z; Ren R
J Hematol Oncol; 2015 Dec; 8():132. PubMed ID: 26715448
[TBL] [Abstract][Full Text] [Related]
15. A Top-Down Proteomic Assay to Evaluate KRAS4B-Compound Engagement.
D'Ippolito RA; Rabara D; Blanco MA; Alberico E; Drew MR; Ramakrishnan N; Sontan D; Widmeyer SRT; Scheidemantle GM; Messing S; Turner D; Arkin M; Maciag AE; Stephen AG; Esposito D; McCormick F; Nissley DV; DeHart CJ
Anal Chem; 2024 Apr; 96(13):5223-5231. PubMed ID: 38498381
[TBL] [Abstract][Full Text] [Related]
16. Origin and evolution of RAS oncoprotein membrane targeting.
García-España A; Philips MR
Res Sq; 2023 Jan; ():. PubMed ID: 36711820
[TBL] [Abstract][Full Text] [Related]
17.
Lu H; Hu Z; Faraudo J; Martí J
Nanoscale; 2023 Dec; 15(47):19359-19368. PubMed ID: 38014474
[TBL] [Abstract][Full Text] [Related]
18. KRas4B-PDE6δ complex stabilization by small molecules obtained by virtual screening affects Ras signaling in pancreatic cancer.
Casique-Aguirre D; Briseño-Díaz P; García-Gutiérrez P; la Rosa CHG; Quintero-Barceinas RS; Rojo-Domínguez A; Vergara I; Medina LA; Correa-Basurto J; Bello M; Hernández-Rivas R; Del RocioThompson-Bonilla M; Vargas M
BMC Cancer; 2018 Dec; 18(1):1299. PubMed ID: 30594165
[TBL] [Abstract][Full Text] [Related]
19. Precise characterization of KRAS4b proteoforms in human colorectal cells and tumors reveals mutation/modification cross-talk.
Ntai I; Fornelli L; DeHart CJ; Hutton JE; Doubleday PF; LeDuc RD; van Nispen AJ; Fellers RT; Whiteley G; Boja ES; Rodriguez H; Kelleher NL
Proc Natl Acad Sci U S A; 2018 Apr; 115(16):4140-4145. PubMed ID: 29610327
[TBL] [Abstract][Full Text] [Related]
20. RAS Nanoclusters Selectively Sort Distinct Lipid Headgroups and Acyl Chains.
Zhou Y; Gorfe AA; Hancock JF
Front Mol Biosci; 2021; 8():686338. PubMed ID: 34222339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
